Allergan PLC is making a foray into gene therapy with the acquisition of privately-held RetroSense Therapeutics LLC, the developer of a novel gene therapy, RST-001, for the treatment of the rare disease retinitis pigmentosa.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?